Wednesday, July 08, 2026

Why Do Elephants Rarely Get Cancer & What It Means For Us?

It is estimated that almost 10 million people die from cancer annually. Even with the widespread advancements we've made in science and technology, the complete cure for cancer has eluded humankind for long. What’s worse, it’s not just humans who are suffering from this disease. You would be surprised to know that the mortality rate in the animal kingdom due to cancer is quite similar to that of humans. 

A lot of you must be aware that pet dogs and cats are often diagnosed with various forms of cancer. Wild animals get cancer, too. Tasmanian devils, sea lions, beluga whales, among others, often die as a result of being afflicted with this disease. 

One animal, however, doesn’t seem to get cancer that often – the elephant. In fact, only about 5% of elephants die from cancer. This is remarkably low for an animal that is so large in size.

Can elephants provide the solution to fight cancer? 

Elephants, the giants of the wild, have an average life span of 60-70 years, which is considered unusual for an animal that is so large. If we go by statistics, bigger animals have more cells, and hence, should have greater occurrences of cancer. This is simply because their cells are dividing so quickly they should just have really high rates of mutation and cancer. But that isn’t the case with elephants. This phenomenon is called “Peto’s paradox”, named after the scientist Richard Peto, who observed that cancer prevalence is not correlated with body size.

The “zombie gene” and how it helps elephants remain largely cancer-free 

Now, a new study has offered clues in regard to the elephant's apparent immunity to cancer, which could lead to being a breakthrough from a medical standpoint. Apparently, elephants have, what researchers are saying, a “zombie gene”. In other words, these animals have extra copies of two cancer-fighting genes. Firstly, there is P53, which hunts for cells with miscopied DNA. The other and more significant one is Leukemia Inhibitory Factor or LIF – a gene that eliminates the mutated cells before they can form a tumor.

Interestingly, a majority of mammals have one copy of LIF. But elephants have 7 to 11 of them. The one that is doing the job for these giant mammals appears to be Leukemia Inhibitory Factor Pseudogene or LIF6. So far, this has only been found in elephants, and this is what scientists believe is helping their bodies remain mostly cancer-free. 

On checking the evolutionary record of these animals, it was later discovered that the LIF6 had actually become inactive in elephant DNA millions of years ago. Curiously, though, it then mysteriously resurrected itself. Initially, it was a broken and useless gene. However, as the elephants evolved, so did the genes, and the LIF6 managed to reawaken in them as a working “zombie gene”.

How the LIF6 gene works in elephants 

To illustrate the significance of the LIF6 gene, scientists carried out lab experiments where they caused DNA damage to African elephant cells. The damage appeared to trigger P53 to turn on the LIF6 gene which then went on to destroy the impaired cells. Furthermore, when the LIF6 was prevented from functioning, the elephant-specific sensitivity to cell damage seemed to disappear. 

Scientists also believe that the LIF6 gene is not the only one keeping cancer in check in elephants. “LIF6 is playing a small part in a broader process,” says Vincent Lynch, an evolutionary biologist at the University of Chicago. Joshua Schiffman, a pediatric oncologist at the University of Utah, agrees, and adds: “there are almost certainly going to be other findings as well.” 

In 2018, a team of scientists published a study that laid emphasis on another set of genes that helps in repairing broken elephant DNA instead of killing damaged cells. Further studies are being conducted in this regard which could lead to significant breakthroughs in understanding how the elephant remains largely immune to cancer. 

Importance of P53 - the tumor-suppressing gene in elephants 

Meanwhile, the importance of the tumor-suppressing gene P53 in elephants cannot be undermined, too. Before the LIF6 gene was discovered, scientists believed that it was P53 that helped elephants remain mostly cancer-free. In 2015, Schiffman and his team had published a paper that found that elephants have extra copies of P53. Humans have one copy of this gene while elephants have 20.

“P53 can recognize DNA damage and then go, ‘OK what are our options?’” explains Amy Boddy, a biologist at the University of California, Santa Barbara. Cells that have normal issues can be repaired. However, the ones with severe damage become prone to cancer. This is where the P53 steps in and orders those cells to be killed in elephants. Furthermore, P53 also stops the cell from proliferating. That gives it the time to repair itself when damaged. 

Thus, with these two super genes – the P53 and the LIF6 – the elephant has managed to fight off cancer for so long.

What does this mean for humans? 

Bowhead whales and blind mole rats are some of the other animals in the wild who have managed to found ways to live long lives without suffering from this dreaded disease. Perhaps, the more we understand about the basic biology of all these animals, the more it would help humans in the longer run. 

Currently, scientists are working with pediatric oncologists, the zoo, and the circus to learn from elephants. The ultimate goal is to attain a complete understanding of the elephants’ defense mechanism against cancer and to use it in the cancer treatments for humans.


This is only for your information, kindly take the advice of your doctor for food, medicines, exercises and so on.   


Labels: , , , , ,

Sarcopenia Affects Nearly 1 in 5 with Rheumatoid Arthritis

NEARLY one in five people with rheumatoid arthritis also has sarcopenia, the progressive loss of muscle mass and strength, a study of almost a thousand patients finds, identifying who is most at risk and hinting that some biologic drugs may protect against it. 

Muscle Loss in Rheumatoid Arthritis 

People with rheumatoid arthritis (RA) are prone to sarcopenia, which erodes physical function and quality of life and may raise mortality. Chronic inflammation is thought to drive it, yet its prevalence under the latest diagnostic criteria was unclear. This study measured how common sarcopenia is in rheumatoid arthritis and which clinical factors mark it out. 

Study Design and Sarcopenia Assessment 

The cross-sectional study enrolled 978 patients with RA (mean age 60.1 years; 86.4% female) diagnosed by the 2010 ACR/EULAR criteria. Sarcopenia was defined using the Asian Working Group for Sarcopenia (AWGS) 2025 consensus, with bioelectrical impedance analysis measuring appendicular skeletal muscle mass and handgrip dynamometry gauging strength. Demographic details, clinical parameters, and medication use were recorded, and associations analysed by logistic regression. The observational design assessed patients at a single timepoint, with no intervention or follow-up. 

Risk Factors and Protective Drugs 

Sarcopenia affected 18.6% of patients (182 of 978). Male sex was strongly associated (odds ratio 9.140; 95% CI 5.211 to 16.029), as were longer disease duration (OR 1.046; 95% CI 1.025 to 1.069), higher RF-IgM level (OR 1.002; 95% CI 1.000 to 1.003), and higher prednisone dose (OR 1.094; 95% CI 1.033 to 1.159). Higher body mass index was protective (OR 0.586; 95% CI 0.534 to 0.643). Notably, use of tumour necrosis factor inhibitors (OR 0.502; 95% CI 0.312 to 0.808) and tocilizumab (OR 0.493; 95% CI 0.304 to 0.799) was each linked to lower odds of sarcopenia. 

Guiding Earlier Identification 

The authors concluded that sarcopenia is common in rheumatoid arthritis, with male sex, lower body mass index, longer disease, higher RF-IgM, and higher glucocorticoid use marking elevated risk. Tocilizumab and TNF inhibitors may reduce its incidence, hinting at a protective role worth further study. They advised the findings could help rheumatologists spot at-risk patients earlier, while cautioning that the small male subgroup (13.6%) limits how far the sex-related findings generalise. 

 

This is only for your information, kindly take the advice of your doctor for food, medicines, exercises and so on.   

 

Labels: , , ,